Price Alert

Dicerna Pharmaceuticals I... (DRNA)

NASDAQ: DRNA · Real-Time Price · USD

38.22

0.00 (0.00%)

At close: Apr 24, 2025, 3:47 PM

Dicerna Pharmaceuticals Statistics

Share Statistics

Dicerna Pharmaceuticals has 0 shares outstanding. The number of shares has increased by null% in one year.

Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Institutions (%)	n/a
Shares Floating	n/a
Failed to Deliver (FTD) Shares	n/a
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 4.77M, so 0% of the outstanding shares have been sold short.

Short Interest	4.77M
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.66

Valuation Ratios

The PE ratio is -14.56 and the forward PE ratio is null. Dicerna Pharmaceuticals's PEG ratio is 1.03.

PE Ratio	-14.56
Forward PE	n/a
PS Ratio	9.99
Forward PS	n/a
PB Ratio	11.92
P/FCF Ratio	10.05
PEG Ratio	1.03

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Dicerna Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.48, with a Debt / Equity ratio of 0.38.

Current Ratio	3.48
Quick Ratio	3.48
Debt / Equity	0.38
Debt / EBITDA	-0.47
Debt / FCF	0.32
Interest Coverage	-5660.4

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$544.06K
Profits Per Employee	$-373.33K
Employee Count	302
Asset Turnover	0.23
Inventory Turnover	n/a

Taxes

Income Tax	481K
Effective Tax Rate	-0.43%

Stock Price Statistics

The stock price has increased by 0% in the last 52 weeks. The beta is 0.79, so Dicerna Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.79
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	3,031,618

Income Statement

In the last 12 months, Dicerna Pharmaceuticals had revenue of 164.31M and earned -112.75M in profits. Earnings per share was -1.51.

Revenue	164.31M
Gross Profit	164.31M
Operating Income	-113.21M
Net Income	-112.75M
EBITDA	-110.51M
EBIT	-112.73M
Earnings Per Share (EPS)	-1.51

Full Income Statement

Balance Sheet

The company has 126.02M in cash and 52.18M in debt, giving a net cash position of 73.84M.

Cash & Cash Equivalents	126.02M
Total Debt	52.18M
Net Cash	73.84M
Retained Earnings	-638.06M
Total Assets	n/a
Working Capital	n/a

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 175.11M and capital expenditures -11.75M, giving a free cash flow of 163.37M.

Operating Cash Flow	175.11M
Capital Expenditures	-11.75M
Free Cash Flow	163.37M
FCF Per Share	2.19

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -68.9% and -68.62%.

Gross Margin	100%
Operating Margin	-68.9%
Pretax Margin	-68.62%
Profit Margin	-68.62%
EBITDA Margin	-67.26%
EBIT Margin	-68.9%
FCF Margin	99.43%

Dividends & Yields

DRNA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for DRNA.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a